Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Hartl

Showing results (41-50 of 175) with videos related to

Pageof 18
Sort By:
Nature Reviews. Drug Discovery|July 5, 2023
Investigating the origins of recent pharmaceutical innovationAlexander Schuhmacher, Markus Hinder, Alexander Dodel, et al.
BMC Pulmonary Medicine|March 1, 2014
Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung diseaseEmmanuelle Fantino, Catherine L Gangell, Dominik Hartl, et al.
Drug Discovery Today|January 13, 2025
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)Alexander Schuhmacher, Markus Hinder, Elazar Brief, et al.
Expert Review of Molecular Diagnostics|March 21, 2009
Allergic bronchopulmonary aspergillosis: the hunt for a diagnostic serological marker in cystic fibrosis patientsGaudenz M Hafen, Dominik Hartl, Nicolas Regamey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 28, 2015
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapyAndré M Cantin, Dominik Hartl, Michael W Konstan, et al.
Nucleic Acids Research|October 24, 2017
Cis-regulatory landscapes of four cell types of the retinaDominik Hartl, Arnaud R Krebs, Josephine Jüttner, et al.
BMC Pulmonary Medicine|May 24, 2018
Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasisJürgen Schäfer, Matthias Griese, Ravishankar Chandrasekaran, et al.
Blood Cells, Molecules & Diseases|September 15, 2005
A donor splice site mutation in intron 1 of CYBA, leading to chronic granulomatous diseaseMartin de Boer, Dominik Hartl, Uwe Wintergerst, et al.
Drug Discovery Today|July 30, 2025
Does pharma R&D need a strategic reset? Adapting to a changing US landscapeSebastian Kwisda, Malte Kremer, Niels Sievertsen, et al.
Chest|October 11, 2007
Bronchoalveolar pepsin, bile acids, oxidation, and inflammation in children with gastroesophageal reflux diseaseVitaliy Starosta, Richard Kitz, Dominik Hartl, et al.
Pageof 18

Showing results (41-50 of 175) with videos related to

Sort By:
Pageof 18
Nature Reviews. Drug Discovery|July 5, 2023
Investigating the origins of recent pharmaceutical innovationAlexander Schuhmacher, Markus Hinder, Alexander Dodel, et al.
BMC Pulmonary Medicine|March 1, 2014
Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung diseaseEmmanuelle Fantino, Catherine L Gangell, Dominik Hartl, et al.
Drug Discovery Today|January 13, 2025
Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)Alexander Schuhmacher, Markus Hinder, Elazar Brief, et al.
Expert Review of Molecular Diagnostics|March 21, 2009
Allergic bronchopulmonary aspergillosis: the hunt for a diagnostic serological marker in cystic fibrosis patientsGaudenz M Hafen, Dominik Hartl, Nicolas Regamey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 28, 2015
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapyAndré M Cantin, Dominik Hartl, Michael W Konstan, et al.
Nucleic Acids Research|October 24, 2017
Cis-regulatory landscapes of four cell types of the retinaDominik Hartl, Arnaud R Krebs, Josephine Jüttner, et al.
BMC Pulmonary Medicine|May 24, 2018
Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasisJürgen Schäfer, Matthias Griese, Ravishankar Chandrasekaran, et al.
Blood Cells, Molecules & Diseases|September 15, 2005
A donor splice site mutation in intron 1 of CYBA, leading to chronic granulomatous diseaseMartin de Boer, Dominik Hartl, Uwe Wintergerst, et al.
Drug Discovery Today|July 30, 2025
Does pharma R&D need a strategic reset? Adapting to a changing US landscapeSebastian Kwisda, Malte Kremer, Niels Sievertsen, et al.
Chest|October 11, 2007
Bronchoalveolar pepsin, bile acids, oxidation, and inflammation in children with gastroesophageal reflux diseaseVitaliy Starosta, Richard Kitz, Dominik Hartl, et al.
Pageof 18